ArticleDermatology and therapy2026
Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
introductionAlopecia areata (AA) is an autoimmune disorder characterized by non-scarring hair loss due to immune dysregulation. Despite advances, its precise molecular mechanisms remain unclear. This study investigates plasma microRNA (miRNA) expression profiles in patients with AA to identify biological pathways influenced by miRNAs and potential therapeutic targets.
methodsA total of 50 patients with AA were categorized as severe or mild on the basis of Severity of Alopecia Tool (SALT) scores. Plasma miRNA levels were compared with those of healthy controls and individuals with other immune-mediated skin diseases. In the discovery phase, 754 miRNAs were analyzed in 20 participants (5 severe AA, 5 mild AA, and 10 controls). Key miRNAs identified were then validated in a second cohort of 90 participants, including patients with AA, non-segmental vitiligo, atopic dermatitis (AD), psoriasis (PsO), and healthy controls, using real-time polymerase chain reaction (RT-PCR). Machine learning was used to classify patients on the basis of their miRNA profiles, and pathway enrichment analysis and drug targeting were conducted to explore therapeutic opportunities.
resultsIn total, 19 miRNAs were significantly downregulated in AA, with 9 technically and clinically validated for both mild and severe forms. The top four miRNAs with the highest classification potential were miR-130b-3p, miR-296-5p, miR-424-5p, and miR-195-5p. Distinct upregulation patterns were identified in vitiligo, AD, and PsO. Machine learning models showed vital classification accuracy for AA (AUC = 0.94) and PsO (AUC = 0.88), with moderate performance for non-segmental vitiligo and AD. Pathway enrichment analysis highlighted immune-related pathways, including the interferon-gamma and Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathways. Drug repositioning identified kinase inhibitors showing the most significant promise for reversing miRNA dysregulation.
conclusionsThis study identifies distinct plasma miRNA profiles in AA, with potential applications for both diagnosis and therapy. Machine learning validated its solid predictive accuracy, and pathway analysis highlighted key immune pathways in AA. These findings should be interpreted as exploratory and hypothesis-generating, pending further functional validation of candidate miRNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.